Comparison of Acebrophylline vs Theophylline on Chronic Obstructive Pulmonary Disease

Abstract

Over the past few decades, there has been a positive increase in the use of pharmaceutical treatment for chronic obstructive pulmonary disease (COPD). Methylamines are often used in COPD patients. Theophylline is a well-known bronchodilator and anti-inflammatory medication, and acebrophylline is a relatively recent addition to contemporary respiratory care. Both are used as adjunctive therapy for patients with stable COPD who are receiving long-acting muscarinic antagonists (LAMAs). One of the world's most pressing public health issues at the moment is chronic obstructive pulmonary disease (COPD). Oral medication therapy is utilised as a second- or third-line maintenance treatment for COPD, while inhaled treatments constitute the first-line maintenance treatment. In comparison to inhaled therapy, oral medications exhibit modest bronchodilator and anti-inflammatory properties, albeit at a lesser concentration. A number of benefits of oral medication therapy include its rapid availability, cloudiest pharmacologic methods of action, convenience of administration, lack of complications with correct inhalational drug deposition in lung airways, and cost-effectiveness.